Literature DB >> 8723296

The outpatient management of febrile neutropenia in cancer patients.

A G Freifeld1, P A Pizzo.   

Abstract

Treatment of fever and neutropenia in cancer patients has been recognized for 30 years as a medical emergency, requiring prompt in-hospital evaluation and institution of broad-spectrum intravenous (i.v.) antibiotics. This action was deemed necessary due to the high frequency of life-threatening infections in febrile neutropenic patients, with no way to distinguish patients who are infected from those who are not. In recent years, it has become clear that not all neutropenic cancer patients are at the same level of risk for developing severe infections or life-threatening complications during neutropenia. Those who are at low risk may be candidates for treatment outside the hospital setting, either with i.v. regimens or potent oral antibiotics. The identification of low-risk febrile neutropenic patients and the specific outpatient approaches that have been tested to date are discussed. Outpatient management of fever during neutropenia could obviously be much less costly than standard inpatient care and could improve quality of life for low-risk patients undergoing cancer therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8723296

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  3 in total

Review 1.  Management of febrile neutropenia in low risk cancer patients.

Authors:  B A Oppenheim; H Anderson
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

Review 2.  [Febrile neutropenia: practical aspects].

Authors:  P Harten; B Seyfarth; N Schmitz
Journal:  Med Klin (Munich)       Date:  1998-10-15

Review 3.  Update on Febrile Neutropenia in Pediatric Oncological Patients Undergoing Chemotherapy.

Authors:  Federica Cennamo; Riccardo Masetti; Prisca Largo; Alberto Argentiero; Andrea Pession; Susanna Esposito
Journal:  Children (Basel)       Date:  2021-11-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.